Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach
Hongyong Zhang(First Affiliated Hospital of Xi'an Jiaotong University), Chong-xian Pan(VA Boston Healthcare System), Primo N. Lara, Christopher P. Evans(University of California, Davis), Xiaobing Wang(University of Science and Technology of China), Paul T. Henderson(UC Davis Comprehensive Cancer Center), James A. Bassuk(Seattle Children's Hospital), Olulanu H. Aina(University of California, Davis), Ralph de Vere White(University of California, Davis), Kit S. Lam(UC Davis Comprehensive Cancer Center)
Cited by 53
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Combination strategies to maximize the benefits of cancer immunotherapy
|Journal of Hematology & Oncology|2021|651
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2011|320
Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers
|Advanced Drug Delivery Reviews|2013|295